Good Day BIO Newsletter

BIO President & CEO John F. Crowley explored the meaning of “innovation, access, and advocacy” at the American Cancer Society Cancer Action Network breakfast yesterday—we have a recap, plus how caregivers are helping researchers find ALS biomarkers. (598 words, 2 minutes, 59 seconds)

A recent WHO report says the pipeline for antibacterials is insufficient to meet the threat of antimicrobial resistance. Meanwhile, the panel deciding whether Mexico’s plan to ban biotech corn violates the U.S.-Mexico-Canada trade agreement is expected to meet this week. (605 words, 3 minutes, 1 second)

The end of last week brought progress on reauthorizing the Pediatric Priority Review Voucher (PPRV) program, and the New York Times turned up the heat on PBMs. (574 words, 2 minutes, 52 seconds)

We launch our new series highlighting companies supported by the NIH SEED program at the NIH Innovation Zone at BIO 2024—today, meet a company using AI to help clinicians assess the effectiveness of neurological and psychiatric therapies. Plus, BIO joins the SAF Coalition and a lot more news. (604 words, 3 minutes, 1 second)

BIO explains why CMS overreach will impede innovation, and we look at how data can improve clinical trial diversity. (532 words, 2 minutes, 39 seconds)

The FDA approved Merck’s vaccine against pneumococcus bacteria, and a former White House official explains why current Medicare policy will harm access to Alzheimer’s treatments. We’re off tomorrow for Juneteenth—which is also World Sickle Cell Day. We explore biotech’s role in reducing inequities that remain. (648 words, 3 minutes, 14 seconds)We're off Wednesday, June 19, for Juneteenth. We'll return to the regular publishing schedule on Thursday, June 20. 

Starting a new week with a look back at what patient advocates said at BIO 2024, and why patient stories matter—plus, rising temperatures nationwide are a reminder of the need to advance biotech solutions. (640 words, 3 minutes, 12 seconds)

We catch up on a few things from D.C. this week: the creation of the Congressional Sustainable Aviation Caucus, Members of Congress calling for value-based payment models, and more praise for an FDA advisory panel’s donanemab recommendation. (635 words, 3 minutes, 10 seconds)

A new report details the economic impact of America’s industrial bioeconomy, while a few recent studies define and quantify the impacts of long COVID. We have details, plus more on reducing the industry’s emissions from BIO 2024. (707 words, 3 minutes, 32 seconds)

New gene therapies will be here soon—but payment models are stuck in the 20th century, said experts at the BIO International Convention. Plus, the onus is on innovators to educate regulators about their science—a few companies explain why. (584 words, 2 minutes, 55 seconds)